CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.
After turning over more than 1,300 documents to the Federal Trade Commission, the fast food giant is turning its attention to subpoenas from pharmacy benefit managers the agency accuses of ...
Bearish flow noted in CVS Health (CVS) with 13,937 puts trading, or 2x expected. Most active are Mar-25 60 puts and Feb-25 63 puts, with total ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
The Justice Department is investigating UnitedHealth's Medicare billing practices, focusing on diagnoses that led to higher ...
CVS Health Corp. closed 19.39% short of its 52-week high of $80.75, which the company reached on March 28th.
CVS Health has named Ed DeVaney president of the company's CVS Caremark pharmacy benefits manager business, CVS announced this week. DeVaney ascends to the top post after having been named interim ...
Two counties in the Charlotte area have filed lawsuits in the last few weeks over the price of insulin. Gaston County and ...
We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...
A federal judge denied a bid by CVS Health, Cigna and UnitedHealth Group to block the Federal Trade Commission's pricing case ...
The price of CVS stock has increased by 48.80% since Jim Cramer called the overall situation fraught. So, what happened?
Our drive to greater drug pricing transparency through innovation has never been more needed,” Ed DeVaney says.